Shots:
- Intellia Therapeutics completed enrollment in the global P-III (HAELO) study evaluating lonvo-z for treating HAE, finishing within 9mos. since the first patient was dosed in Jan 2025, with nearly half of the participants enrolled from the US
- The study P-III (HAELO) study will evaluate the efficacy and safety of lonvo-z in ≥60 adults and adolescents aged 16yrs. and older with Type I or Type II HAE
- Topline P-III data are expected in 1H 2026; the company plans to submit a BLA in 2H 2026 to enable a potential US launch in 1H 2027. Intellia also plans to present long-term data from the Phase 1/2 study in Q4 2025
Ref: Intellia Therapeutics | Image: Intellia Therapeutics | Press Release
Related News:- Intellia Therapeutics Reports the First Patient Dosing in P-III (MAGNITUDE-2) Trial of Nexiguran Ziclumeran for ATTRv-PN
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
